Dicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting[R] 2021 in November

Source :: Business Wire. October 14, 2021
Publication Year :: 2021
Abstract: LEXINGTON, Mass. -- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that two abstracts related to the Company's clinical development programs [...]

Subjects :: Medical research -- Health aspects
Medicine, Experimental -- Health aspects
RNA -- Health aspects
Liver diseases -- Health aspects
Business
Business, international

Tools